[A20-39] Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 15.07.2020
Project no.:
A20-39
Commission:
Commission awarded on 03.04.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
previously untreated chronic lymphocytic leukaemia
Result of dossier assessment:
Added benefit not proven for any of the three research questions
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-81 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-82 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G16-14 | Venetoclax (chronic lymphocytic leukaemia) – Assessment according to § 35a (para. 1, sentence 10) Social Code Book V | Commission completed |
| A20-76 | Venetoclax (chronic lymphocytic leukaemia) - Addendum to Commission A20-39 | Commission completed |
| A21-82 | Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |